Sanara MedTech Reports Strong FY25 Revenue Growth and Reaffirms FY26 Guidance Amidst Strategic Realignment

summarizeSummary

Sanara MedTech Inc. announced its Q4 and full-year 2025 financial results, reporting 19% full-year revenue growth and a near-doubling of Adjusted EBITDA, while reaffirming its 2026 revenue guidance.

check_boxKey Events

• Strong Full Year 2025 Revenue Growth

  Net revenue increased 19% year-over-year to $103.1 million for the full year 2025, or 22% excluding extraordinary BIASURGE sales in Q4 2024.

• Significant Adjusted EBITDA Improvement

  Full year 2025 Adjusted EBITDA nearly doubled to $17.0 million, compared to $9.1 million in 2024, demonstrating improved profitability.

• Reaffirmed Full Year 2026 Financial Guidance

  The company reaffirmed its 2026 net revenue guidance of $116 million to $121 million, representing 13% to 17% growth, indicating confidence in continued performance.

• Strategic Realignment and Impairment Charges

  The company recorded a $26.5 million non-cash asset impairment charge in 2025 related to discontinued operations (Tissue Health Plus) and a $1.8 million charge for IP assets in Q4 2025, reflecting a strategic shift to focus on the surgical market.

auto_awesomeAnalysis

Sanara MedTech Inc. reported robust full-year 2025 financial results, highlighted by significant revenue growth and improved Adjusted EBITDA, which are key indicators of operational health. The company's strategic realignment, which led to substantial asset impairment charges, provides clarity on its future focus on the surgical market. While the net loss from continuing operations in Q4 2025 and the increase in long-term debt are areas for investor attention, the reaffirmation of strong 2026 revenue guidance suggests management confidence in the company's core business trajectory. This filing provides critical insight into the company's financial performance and strategic direction, especially as the stock trades near its 52-week low, potentially signaling a turning point for investors.